We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology of Schizophrenia in Bulgaria

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00984373
First Posted: September 25, 2009
Last Update Posted: February 4, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose

The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of:

  • Patient characteristics.
  • Diagnostic and treatment approaches: initial and subsequent.

Condition
Schizophrenia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 440
Study Start Date: September 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary Care Clinic
Criteria

Inclusion Criteria:

  • Patients with schizophrenia
  • Above 18 years
  • Signed Informed consent

Exclusion Criteria:

  • Below 18 years
  • Consent refused
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984373


Locations
Bulgaria
Research Site
Burgas, Bulgaria
Research Site
Pazardzhik, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vidin, Bulgaria
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00984373     History of Changes
Other Study ID Numbers: NIS-NBG-SER-2009/1
First Submitted: September 24, 2009
First Posted: September 25, 2009
Last Update Posted: February 4, 2010
Last Verified: February 2010

Keywords provided by AstraZeneca:
Schizophrenia epidemiology
Schizophrenic patients' social and health characteristics

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders